MARKET

KZIA

KZIA

Kazia
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.21
-0.24
-2.10%
Closed 16:00 09/24 EDT
OPEN
11.27
PREV CLOSE
11.45
HIGH
11.50
LOW
11.12
VOLUME
9.61K
TURNOVER
--
52 WEEK HIGH
15.85
52 WEEK LOW
5.55
MARKET CAP
148.59M
P/E (TTM)
-19.9253
1D
5D
1M
3M
1Y
5Y
Kazia Therapeutics to Present at HC Wainwright 23rd Annual Global Investment Conference
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the HC Wainwright 23rd Annual Global Investment Conference, to be held virtually from...
PR Newswire · 09/10 16:30
Investing in Kazia Therapeutics (ASX:KZA) three years ago would have delivered you a 241% gain
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company...
Simply Wall St. · 09/07 22:36
Kazia Therapeutics Announced EVT801 Phase I Study Receives Full Regulatory Approval in France
Kazia Therapeutics Limited (NASDAQ: KZIA) is pleased to inform stakeholders that the planned phase I study for EVT801 has received full approval from L'Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM), the French regulatory agency...
Benzinga · 09/02 09:35
When Will Kazia Therapeutics Limited (ASX:KZA) Breakeven?
With the business potentially at an important milestone, we thought we'd take a closer look at Kazia Therapeutics...
Simply Wall St. · 08/02 21:31
Kazia Calls for Increased Focus on Brain Cancer Research this GBM Awareness Day
/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a leading drug development company in the field of brain cancer, today recognizes Glioblastoma (GBM) Awareness Day and calls for a greater focus on research from industry, academia, and g...
PR Newswire - PRF · 07/21 14:00
BRIEF-Kazia Therapeutics Provides Progress Update On Paxalisib And Evt801 Clinical Programs
reuters.com · 06/30 14:36
Kazia provides progress update on paxalisib and EVT801 clinical programs
Kazia Therapeutics ([[KZIA]] +3.9%) provides an update on recent progress with its two pipeline assets, paxalisib and EVT801.The company's GBM AGILE pivotal study of paxalisib is recruiting ahead of expectations, with
Seekingalpha · 06/30 14:14
Kazia Provides Progress Update on Paxalisib and EVT801 Clinical Programs
/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide an update on recent progress with its two pipeline assets, paxalisib and EVT801.
PR Newswire - PRF · 06/30 14:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of KZIA. Analyze the recent business situations of Kazia through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average KZIA stock price target is 16.83 with a high estimate of 16.83 and a low estimate of 16.83.
EPS
Institutional Holdings
Institutions: 15
Institutional Holdings: 642.55K
% Owned: 4.85%
Shares Outstanding: 13.26M
TypeInstitutionsShares
Increased
4
51.92K
New
4
42.37K
Decreased
2
10.01K
Sold Out
3
15.01K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Non-Executive Chairman
Iain Ross
Chief Executive Officer/Executive Director
James Garner
Other
Gordon Hirsch
Other
Lilischkis Kimberley
Other
Peng Leong
Other
Stephen Palmer
Other
Justine Stehn
Secretary
Kate Hill
Non-Executive Director
Bryce Carmine
Non-Executive Director
Steven Coffey
No Data
About KZIA
Kazia Therapeutics Limited is an Australia-based oncology-focused drug development company. The Company collaborates with clinicians, scientists, and researchers across the world for the development of cancer treatment. The Company’s product candidates include Paxalisib and EVT801. Paxalisib (GDC-0084) is invented by Genentech, Inc (South San Francisco, CA). Genentech, Inc is a developer of new cancer medicines across the world. The Company entered into a license agreement with Genentech. EVT801 targets angiogenesis, the formation of new blood vessels around a tumor. EVT801 is invented by Sanofi SA (Paris, France), and licensed to Evotec SE (Hamburg, Germany). The Company entered into a license agreement with Evotec. EVT801 is ready for Phase I clinical trial.

Webull offers kinds of Kazia Therapeutics Ltd (ADR) stock information, including NASDAQ:KZIA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KZIA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KZIA stock methods without spending real money on the virtual paper trading platform.